Athira Pharma, Inc. logo

Athira Pharma, Inc.

NASDAQ:ATHA

Overview | Financials
Company Name Athira Pharma, Inc.
Symbol ATHA
Currency USD
Price 0.463
Market Cap 17,797,442
Dividend Yield 0%
52-week-range 0.463 - 4.298
Industry Biotechnology
Sector Healthcare
CEO Dr. Mark J. Litton M.B.A., MBA, Ph.D.
Website https://www.athira.com

An error occurred while fetching data.

About Athira Pharma, Inc.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the

Related Stocks

Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc.

FULC

3.44 USD

BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc.

BTAI

0.637 USD

Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc.

HRTX

1.95 USD

HilleVax, Inc. logo

HilleVax, Inc.

HLVX

1.81 USD

Absci Corporation logo

Absci Corporation

ABSI

3.98 USD

ALX Oncology Holdings Inc. logo

ALX Oncology Holdings Inc.

ALXO

2.14 USD

C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc.

CCCC

6.38 USD

Rigel Pharmaceuticals, Inc. logo

Rigel Pharmaceuticals, Inc.

RIGL

13.63 USD

OraSure Technologies, Inc. logo

OraSure Technologies, Inc.

OSUR

4.31 USD

Financials

Numbers are in millions USD

Numbers are in millions USD